September 05, 2018
Tanvex BioPharma, Inc. (TWSE: 6541) completed its secondary public offering of
25,000,000 shares of common stock on September 04, 2018. The new shares were
listed on September 5, 2018.
The pricing for this offering was set at NTD 85 per share, resulting in total gross
proceeds of NTD 2,125,000,000. Tanvex intends to use the net proceeds from this
offering to support the launch of TX-01, and for ongoing manufacturing,
development and clinical trial activities related to TX-05 and TX-16.
Tanvex BioPharma, Inc. (TWSE: 6541) is a biopharmaceutical company focused on the biosimilar market. The Company is vertically integrated with end-to-end in-house development, manufacturing and commercialization capabilities. Tanvex BioPharma, Inc. is registered in Cayman Islands and has operations and facilities in Irvine, CA, San Diego, CA, and Taipei, Taiwan. Tanvex is publicly traded on the Taiwan Stock Exchange.